Related Experiment Videos
[New developments in chemotherapy for experimental brain metastasis]
Abstract:
Numerous animal models of brain tumor have been developed for screening new chemotherapeutic agents effective for brain tumors. However, most of these models have problem (s) of mechanical disruption of the blood-brain barrier by tumor inoculation and/or discrepancy in histologic nature and site of growth between inoculated tumors and human tumors. With the purpose of establishing a better model for the evaluation of antitumor activity, we have developed rat models of leptomeningeal tumors by intralateral-ventricle inoculation of myelogenous leukemia cells (DBLA-6) or AH130 ascites hepatoma cells. It was proved that in the two models there was no disruption of blood-brain barrier function by tumor inoculation and that the histologic pattern of DBLA-6 model tumor closely resembled the diffuse meningeal involvement of leukemic cells seen in the human disease. Using these models, several antitumor agents have been tested and ACNU, CCNU and procarbazine were found to be highly effective when given intravenously or intraperitoneally, and the intralateral-ventricle administration of methotrexate was also found to show a moderate antitumor activity. Furthermore it was found that intraperitoneal administration of spirohydantoin mustard, and intralateral-ventricle administration of 5-fluorodeoxyuridine were highly effective against the AH130 model.
Insights
Researchers developed new rat models for brain tumors to better test chemotherapy drugs. These models avoid blood-brain barrier disruption and accurately mimic human tumor characteristics, showing promise for drug screening.
Area of Science:
- Neuro-oncology
- Pharmacology
- Animal Models
Context:
- Existing animal models for brain tumors often involve mechanical disruption of the blood-brain barrier (BBB) or exhibit histological differences from human tumors.
- These limitations hinder the accurate evaluation of chemotherapeutic agents for brain tumors.
Purpose:
- To develop improved rat models for evaluating antitumor activity.
- To establish models that do not disrupt the blood-brain barrier during tumor inoculation.
- To create models with histological patterns resembling human brain tumors.
Summary:
- Rat models of leptomeningeal tumors were created using intralateral-ventricle inoculation of DBLA-6 leukemia cells or AH130 ascites hepatoma cells.
- These models demonstrated no blood-brain barrier disruption, and the DBLA-6 model closely mimicked human leukemic cell meningeal involvement.
- Testing revealed ACNU, CCNU, and procarbazine were effective intravenously/intraperitoneally; methotrexate showed moderate activity via intralateral-ventricle administration.
- Spirohydantoin mustard (intraperitoneal) and 5-fluorodeoxyuridine (intralateral-ventricle) were highly effective against the AH130 model.
Impact:
- Provides more accurate and reliable animal models for preclinical brain tumor research.
- Facilitates the effective screening and development of novel chemotherapeutic agents for brain tumors.
- Enhances the translational relevance of animal studies to human brain tumor treatment.